Skip to main content
Log in

N-Carbamylglutamate protects patients with decompensated propionicaciduria from hyperammonaemia

  • Short Report
  • Published:
Journal of Inherited Metabolic Disease


In patients with propionic aciduria, the accumulating metabolite propionyl-CoA causes a disturbance of the urea cycle via the inhibition of N-acetylglutamate synthesis. Lack of this allosteric activator results in an inhibition of carbamoylphosphate synthase (CPS). This finally leads to hyperammonaemia. In two patients with decompensated propionic aciduria the CPS activator carbamylglutamate was tested for its ability to antagonize the propionyl-CoA associated hyperammonaemia. Oral carbamyl glutamate administration resulted in a significant increase in ammonia detoxification and could avoid further dialysis therapy. Safe, fast and easy to administer, carbamyl glutamate improves the acute therapy of decompensated propionic aciduria by increasing ammonia detoxification and avoiding hyperammonaemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Author information

Authors and Affiliations


Corresponding author

Correspondence to B. Gebhardt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gebhardt, B., Dittrich, S., Parbel, S. et al. N-Carbamylglutamate protects patients with decompensated propionicaciduria from hyperammonaemia. J Inherit Metab Dis 28, 241–244 (2005).

Download citation

  • Issue Date:

  • DOI: